On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing

Alaunos Therapeutics, Inc. - Common Stock -13.04% Pre

Alaunos Therapeutics, Inc. - Common Stock





0.00% Pre

The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consulting Agreement will continue for a period of six months.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via